Sugammadex + Rocuronium

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Neuromuscular Block

Conditions

Neuromuscular Block

Trial Timeline

Sep 1, 2016 → Jul 1, 2017

NCT ID

NCT02484651

About Sugammadex + Rocuronium

Sugammadex + Rocuronium is a approved stage product being developed by Merck for Neuromuscular Block. The current trial status is completed. This product is registered under clinical trial identifier NCT02484651. Target conditions include Neuromuscular Block.

What happened to similar drugs?

14 of 20 similar drugs in Neuromuscular Block were approved

Approved (14) Terminated (2) Active (6)

✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved

✅Deep neuromuscular block + Moderate neuromuscular blockMerckApproved

✅sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved

✅neostigmine/glycopyrrolate + sugammadexMerckApproved

✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved

✅Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved

✅Sugammadex + NeostigmineMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02484651	Approved	Completed	Sep 1, 2016	Jul 1, 2017	Neuromuscular Block
NCT02451202	Approved	Completed	Jun 1, 2016	Mar 1, 2018	Laryngoscopic Surgical Procedures
NCT00656799	Phase 3	Completed	Apr 1, 2008	Jul 1, 2009	Neuromuscular Blockade
NCT00475215	Phase 3	Completed	Oct 27, 2005	Sep 9, 2006	Anesthesia, General
NCT00298831	Phase 3	Completed	Oct 27, 2005	May 22, 2006	Anesthesia, General

Competing Products

20 competing products in Neuromuscular Block

See all competitors

Product	Company	Stage	Hype Score
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)	Jiangsu Hengrui Medicine	Phase 2	42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + Rocuronium	Jiangsu Hengrui Medicine	Phase 2	42
HRS-9190 + HRS-9190 + HRS-9190	Jiangsu Hengrui Medicine	Phase 2	35
Placebo + Sugammadex + Esmeron®	Merck	Phase 2	35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + Vecuronium	Merck	Approved	43
Deep neuromuscular block + Moderate neuromuscular block	Merck	Approved	39
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + Neostigmine	Merck	Pre-clinical	26
sufficient dose of rocuronium + sugammadex 10 min after position change	Merck	Approved	43
neostigmine/glycopyrrolate + sugammadex	Merck	Approved	43
sugammadex	Merck	Phase 3	40
2 mg/kg sugammadex + 0.07 mg/kg neostigmine	Merck	Phase 3	47
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + Atropine	Merck	Approved	43
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + Succinylcholine	Merck	Approved	35
Sugammadex + Neostigmine	Merck	Approved	43
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or Vecuronium	Merck	Approved	43
sugammadex + Neostigmine + Glycopyrrolate	Merck	Approved	43
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;	Merck	Phase 2	35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + Atropine	Merck	Approved	43
Rocuronium Bromide + Rocuronium Bromide	Merck	Approved	43
Rocuronium (moderate NMB) + Rocuronium (deep NMB)	Merck	Pre-clinical	22